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We have performed 7 experiments in rats on the effects of systemic treatment
with fludorocortisone (9a-FF) given in a variety of doses over a variety of times,
in the AM and in the PM. These experiments were designed to determine the
best treatment protocol to use in the head-down rat model studies which were
performed at NASA-Ames Research Center during the final year. The results of
the experiments in non-stressed rats have been, on the whole, disappointing in
that we have so far been unable to obtain direct evidence that the 9a-FF acts as a
mineralocorticoid. In the ultimate experiments using control and suspended
rats, we showed mineralocorticoid and glucocorticoid effects of 9aFF. However,
suspension served in our rats as a chronic stressor when they were examined 5 d
after the onset of treatment. Below is a list of the experiments that we performed
and the results.
Experiment 1. To devise infusion doses of 9a-FF that should be used in intact
rats, we used adrenalectomized rats and attempted to modify the injection
protocol used by Lim and Funder (J. Clin Invest. 69:1191-1198) to our intended
constant infusion protocol. Young male Sprague Dawley rats weighing 150-175 g
were adrenalectomized and implanted at that time with Alza miniosmotic
pumps which delivered 9a-FF at rates of 0.5, 1.0 and 5 ug/d for 5 days. As in the
Lim and Funder experiments, the rats were maintained on saline to drink (0.5%
NaC1). The animals lost weight in proportion to the rate of 9a-FF infusion (as
seen by Lim and Funder). However, we not only measured endpoints associated
with activity of the hypothalamo-pituitary-adrenal (HPA) axis, but also
measured plasma electrolytes and osmolality. The experiment was a catastrophe;
the rats were scrawny and unwell, HPA axis activity was increased in proportion
to the dose of steroid infused, probably because the rats were sick. With
hindsight, we recognized that the steroid infused animals should have been
taken off saline and allowed to drink water. 9a-FF has a short half life and Lim
and Funder probably got away with keeping their rats on saline because they
injected the steroid only once a day, whereas we were maintaining a constant
elevation in steroid by infusion. Thus, the results of experiment I were not
revealing.
Experiment 2. In this experiment, intact rats were implanted with osmotic
pumps designed to deliver 0, 0.5, 1 and 5 ug 9a-FF/day for 5 days, and the rats
were, of course, allowed to drink water. Three rats from each group lived in
metabolism cages during the experiment; food and water intakes were measured
daily as was urinary Na, K and osmolality. On the morning of d 5, rats were
stressed by being placed in restraining tubes and having blood samples collected
from the tail at 0 and 15 min; the rats were decapitated at 30 rain.
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Results: Again we ran into complexities that we had not anticipated. Because 9a-
FF has high, and equal, affinity for both the mineralocorticoid receptor (MR) and
glucocorticoid receptor (GR), we observed potent interactive effects on both
systems across the range of doses used. These are difficult, if not impossible, to
sort out.
Mineralocorticoid receptor-mediated effects. In terms of effects mediated
probably by association of the steroid with MR, we observed a significant overall
effect of dose on hematocrit, with significant decrease at the highest dose (p=
0.023). This result suggested that at the highest dose at least, the steroid caused
expansion of plasma volume as anticipated. Examination of urinary Na +
excretion showed little effect on days 1,2 and 4 but slightly decreased excretion at
all doses of steroid on d 3-4, which could account for the expansion observed on
d 5 am. Water intake also tended to increase with increasing doses of 9a-FF, agin
compatible with expansion of the ECF volume. However, if these effects were
meaningful, we should have observed consistent, dose-related increases in body
weight gain over the infusion period and we did not. The 2 lower doses caused
slight gains in body weight above that observed in vehicle-infused controls. The
group of rats given the high dose, however, gained the same amount of weight
as the controls over the 5 d period. We believe, see below, that this is because the
group given the high steroid dose exhibited some clear GR-mediated effects
which clearly reduced food efficiency and was on the border of typical
glucocorticoid-mediated catabolic actions.
Glucocorticoid receptor-mediated effects. Food intake increased slightly but
consistently with increasing rates of steroid infusion. Although pituitary ACTH
concentration and the plasma ACTH response to stress did not change as a
function of steroid infused, adrenal weight was significantly reduced by the
steroid in a dose-related fashion (p=0.009), with the highest dose causing
significantly smaller adrenals. Adrenal corticosterone (B) content tended to
decrease in the stressed rats with steroid infusion (p = 0.108), however there was
no effect of the steroid infusion on thymus weight. This result would be
anticipated, since it is likely (although not measured here) that the exogenous
infusion of glucocorticoid caused the endogenous system to decrease its activity
to the extent possible. It seems likely that only at the highest dose of steroid
infused was the endogenous system overwhelmed (as judged by adrenal
weight). Plasma glucose concentrations in the 30 min stress samples were
uniformly high.
From this experiment we thought the results were encouraging enough that a
further experiment using chronic treatment was warranted.
Experiment 3. In this experiment heavier rats were used (final weight - 250-
270g) and oil, 2, 10, or 20 ug/rat/day 9a-FF was given in the morning by
intramuscular injection for 4 d. We hoped with this approach to increase the
mineralocorticoid and decrease the glucocorticoid effects of the steroid. Again, 3
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rats from each experimental group lived in metabolism cages over the 5 d. The
results were disheartening. Presumably because the last steroid injection had
been given 28 h previously, there was no effect of the steroid treatment regimen
on plasma volume or urinary Na excretion after the volume load. However,
there were also no significant effects of the steroid treatment on any of the
endpoints examined, although there was a tendency toward reduced adrenal and
thymus weights with dose of 9a-FF, and a consistent, but non-significant
tendency for increasing steroid dose to inhibit the ACTH response to restraint
(Fig. 1). There were no discernable mineralocorticoid effects in the endpoints
measured. If anything, urinary Na+ excretion increased with increasing steroid;
however that may have been a consequence of the slightly increased food intake
that occurred as a function of the steroid dose, since the rats ate normal rat chow
that has a high Na content.
We abandoned the chronic treatment approach as unsuitable and adopted a new
approach that is more in line with the preventive treatment paradigm now being
examined for efficacy in ground based simulations. In the final sets of studies,
groups of rats were injected with 20 ug 9a-FF 0, 1, or 2 X, each injection separated
by 12 h, the last injection given 2 h before testing. Vehicle-injected controls were
used and all rats received a total of 2 injections of either vehicle or steroid. The
studies were carried out in both the AM and in the PM, with the experiments
performed entirely at the NASA-Ames Research Center. All of the previously
mentioned endpoints were measured and, 2 h after the final injections of 9aFF or
vehicle, rats were injected under ether anesthesia with Evans' Blue for
determination of plasma volume after they were killed 10 min later. The animals
were either treated as controls or were placed in suspension for 5 d prior to being
injected at -14 and -2 h with either 0, 1 or 2 doses of 9aFF.
Results: In encapsulated form, the conclusion from these studies is that
suspended rats are chronically stressed. Although we saw the largest effects of
9aFF on body Na whan only one injection was given 2 h before killing the rats,
this effect was essentially swamped by the chronic effects of tail suspension
when these rats were compared to control. When 2 injections of 20 ug 9aFF were
given at 12 h intervals (14 and 2 h prior to death of the animals), endogenous
responses to the first injection appear to have swamped the effects of the second
injection.
Fig 2. Shows changes in body weight and food efficiency across the 5 days
of the study. The increase in body weight was significantly diminished in the
suspended rats, both in the AM and PM studies. This is because, although food
consumption was only marginally decreased, food efficiency (grams of weight
gained/gram of food consumed) was markedly and consistently reduced in the
suspended rats.
Fig 3. shows urinary Na output during days 2-4 of suspension. Although
there was no difference in Na output in the AM study, there was a significant
overall effect of suspension in reducing Na output because in the PM group,
there was a highly significant decrease in Na output in the suspended, compared
to the control rats. This was true for both the AM and PM groups during the last
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24h of suspension; however, injection of 9aFF14h prior to killing the rats caused
an increasein Na output in the suspension group in the AM and in the control
group in the PM. One injection of 9aFF2 h prior to death causeda significant
decreasein plasma protein, suggesting the expectedexpansion of plasma
volume, in all groups of rats treated with the mineralocorticoid; however after 2
injections of 9aFF,14and 2 h prior to death, the rats had apparently accomodated
the the mineralocorticoid injection and there were no differences from untreated
rats in plasma protein.
Fig 4. shows adrenal (top) and thymus (bottom) weights for these rats.
There was asignificant increasein adrenal weight in the suspended rats
compared to controls again, aswith body weight gains and caloric efficiency,
suggesting that chronic suspensionis a chronic stressor. The degreeof chronic
stress (in terms of putative excessivecorticosteronesecretion) is mild, since there
was not a significant effect of suspension on thymus weight. Markedly elevated
corticosterone over 5 days would have decreasedthymus weights significantly.
Fig 5. shows plasma renin activity (top) and aldosterone concentrations
(bottom) 10min after the onset of ether stressand injection. Thesevalues clearly
represent stressedlevels of both substances. However, renin responsesto ether
were greater in the suspended rats than in the controls at both times of day,
suggesting that there is facilitation (seebelow) not only in the adrenocortical
system but also in the sympathetic nervous system asa consequenceof chronic
stress. The fact that 9aFFinjections markedly reduced the renin responsesin the
suspended rats to ether stresssuggeststhat the steroid does act centrally on SNS
output to the periphery to inhibit this system when it is excited. By contrast, to
the renin responseswhich arenot affected by the ACTH response to acute stress,
the aldosterone responsesreflect primarily the ACTH secretion that occurred
after ether (seeFig 6). Aldosterone responsesin the suspended rats were greater
than control in the AM but not in the PM. Prior treatment with 9aFF reduced the
aldosterone responsesin a dose-related fashion at both times of day (except for
the small responsein the AM control rats).
Fig 6. shows plasma ACTH (top), and adrenal (middle) and plasma
corticosterone (B) responses(bottom) 10min after ether in the AM and PM in
control and suspended rats. That suspension is a chronic stressor is
unequivocally establishedby the ACTH results. In prevous and subsequent
studies of the effectsof chronic stresson responsesto acutenovel stress(using
either streptozotocin-diabetes or cold for 5 d; [Scribner, 1993;Akana, 1994;
Akana, 1992;Akana, 1997;Akana, 1996]), we have observed that the previously
stressedrats hypersecreteACTH to novel stressin the AM but not the PM. This
is clearly the casewith rats that have beensuspended for 5 d aswell. There was
a significantly greater ACTH response to ether in the AM in the suspended rats,
compared to controls, and no difference in the PM from controls. Furthermore,
asshown previously with corticosterone treatment, inhibition of the ACTH
responseby 9aFFwas highly significant in the AM but far lessso in the PM.
Adrenal and plasma B,again as in previous studies, show facilitation in the PM,
not the AM; just the opposite from ACTH. However, we had no basal samples in
thesestudies, and in previous studies we showed that the effect of facilitation in
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the PM was on basal levels of ACTH and B and that the magnitude of the
response to stress was the same in previously stressed vs control ratsf Akana,
1992; Akana, 1997].
In summary: The experiments show that a single, but not multiple doses of
9aFF does work to expand extracellular fluid volume in rats, as in man.
Furthermore, rather than stimulating the sympathetic neurvous system as it was
hypothesized it might, it appears that 9aFF may inhibit the response of the SNS
to acute stress (based on the the inhibited PRA response to ether stress). Tail
suspension of rats as a model for weightlessness in man definitely appears to be
a persistant stressor over at least the first 5 d, based on decreased body weight
gain, caloric efficiency, enlarged adrenal glands and hyperresponsivity of the
HPA axis to a novel stress in the AM. This effect of suspension in rats resembles,
we believe, the effects of space flight in man although the stressor in rats is
probably not the same as that in man. In reports of urinary cortisol excretion
during space flights, on average cortisol excretion doubles (JAP, July 1996). In
man, the persistent stressor encountered during space flight may be either the
heavy work load, the early alterations in appetite accompanied by nausea or the
possible lack of a normal circadian rhythm in cortisol. Whatever the proximate
cause of the increased cortisol excretion (and probably adrenal secretion) during
space-flight, the elevated cortisol concentrations would be expected to reinforce
the negative nitrogen balance that is ascribed to muscle atrophy and the immune
system dysfunction that have been observed in space. It is interesting that rats
in space show no signs of excessive corticosterone secretion (JAP, 1996). Clearly
in the best ground-based simulation, tail tweaking involved with suspension is a
stressor - as shown by Alonso et al. (AJP, 1994) in both suspended and non-
suspended but tail-treated rats compared to untreated controls. These animals
may still serve as useful models for man in space, simply because they exhibit
characteristics of elevated ACTH and corticosterone secretion similar to those
observed in man in space.
Submi_ed 1/16/98.
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Response to restraint on d 5 (Rats treated with 9aFF days 1-4)
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